| Dr James Creed Spann, MD | |
|
2708 S Rife Medical Ln Ste 210, Rogers, AR 72758-1456 | |
| (793) 383-8888 | |
| (479) 338-4453 |
| Full Name | Dr James Creed Spann |
|---|---|
| Gender | Male |
| Speciality | Thoracic Surgery |
| Experience | 33 Years |
| Location | 2708 S Rife Medical Ln Ste 210, Rogers, Arkansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134209273 | NPI | - | NPPES |
| 100074920A | Medicaid | OK | |
| 134328001 | Medicaid | AR | |
| 1134209273 | Other | OK | OK STATE EMPLOYEES (HEALTHCHOICE |
| 295A | Other | AR | MEDICARE |
| 5I124 | Other | AR | BLUE CROSS BLUE SHIELD |
| P01068164 | Other | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208G00000X | Thoracic Surgery (cardiothoracic Vascular Surgery) | 20598 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercy Hospital Northwest Arkansas | Rogers, AR | Hospital |
| Hillcrest Medical Center | Tulsa, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ahs Oklahoma Heart Llc | 4587737135 | 109 |
| Mercy Health Northwest Arkansas Communities | 0648177873 | 265 |
News Archive
Close to one million newborns will die in 2020 because they do not start breathing at birth. In addition, breathing problems at birth will result in much more developing brain damage. Getting air immediately into the lungs of any non-breathing newborn can help prevent brain damage.
People with Icelandic heritage are more likely to carry a novel rare mutation in the TM2D3 gene, which leads to greater risk for Alzheimer's disease, based on a new study published October 14th, 2016 in PLOS Genetics by Johanna Jakobsdottir of the Icelandic Heart Association, Sven van der Lee of Erasmus University in Rotterdam, and colleagues.
Advanced Cell Technology, Inc., a biotechnology company applying cellular technology in the field of regenerative medicine, announced today that it has received notification from the US Food and Drug Administration (FDA) that the Agency is currently drafting a response to the Company relating to the Investigational New Drug (IND) Application it filed in November seeking clearance to initiate a Phase I/II multicenter study using embryonic stem cell derived retinal cells to treat patients with Stargardt's Macular Dystrophy (SMD).
Respiratory movement during radiotherapy makes it difficult to hit the right treatment target and this in turn can lead to an under-dose of radiation to the tumour, or a potentially toxic over-dose to the surrounding healthy tissue. Getting this right is a real challenge for the radiotherapist, but new techniques are helping to deliver the correct dose to the right place, the 31st conference of the European Society for Radiotherapy and Oncology (ESTRO 31) will hear today.
› Verified 6 days ago
| Entity Name | Ahs Oklahoma Heart Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780857540 PECOS PAC ID: 4587737135 Enrollment ID: O20080716000032 |
News Archive
Close to one million newborns will die in 2020 because they do not start breathing at birth. In addition, breathing problems at birth will result in much more developing brain damage. Getting air immediately into the lungs of any non-breathing newborn can help prevent brain damage.
People with Icelandic heritage are more likely to carry a novel rare mutation in the TM2D3 gene, which leads to greater risk for Alzheimer's disease, based on a new study published October 14th, 2016 in PLOS Genetics by Johanna Jakobsdottir of the Icelandic Heart Association, Sven van der Lee of Erasmus University in Rotterdam, and colleagues.
Advanced Cell Technology, Inc., a biotechnology company applying cellular technology in the field of regenerative medicine, announced today that it has received notification from the US Food and Drug Administration (FDA) that the Agency is currently drafting a response to the Company relating to the Investigational New Drug (IND) Application it filed in November seeking clearance to initiate a Phase I/II multicenter study using embryonic stem cell derived retinal cells to treat patients with Stargardt's Macular Dystrophy (SMD).
Respiratory movement during radiotherapy makes it difficult to hit the right treatment target and this in turn can lead to an under-dose of radiation to the tumour, or a potentially toxic over-dose to the surrounding healthy tissue. Getting this right is a real challenge for the radiotherapist, but new techniques are helping to deliver the correct dose to the right place, the 31st conference of the European Society for Radiotherapy and Oncology (ESTRO 31) will hear today.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr James Creed Spann, MD 2708 S Rife Medical Ln Ste 210, Rogers, AR 72758-1456 Ph: (793) 383-8888 | Dr James Creed Spann, MD 2708 S Rife Medical Ln Ste 210, Rogers, AR 72758-1456 Ph: (793) 383-8888 |
News Archive
Close to one million newborns will die in 2020 because they do not start breathing at birth. In addition, breathing problems at birth will result in much more developing brain damage. Getting air immediately into the lungs of any non-breathing newborn can help prevent brain damage.
People with Icelandic heritage are more likely to carry a novel rare mutation in the TM2D3 gene, which leads to greater risk for Alzheimer's disease, based on a new study published October 14th, 2016 in PLOS Genetics by Johanna Jakobsdottir of the Icelandic Heart Association, Sven van der Lee of Erasmus University in Rotterdam, and colleagues.
Advanced Cell Technology, Inc., a biotechnology company applying cellular technology in the field of regenerative medicine, announced today that it has received notification from the US Food and Drug Administration (FDA) that the Agency is currently drafting a response to the Company relating to the Investigational New Drug (IND) Application it filed in November seeking clearance to initiate a Phase I/II multicenter study using embryonic stem cell derived retinal cells to treat patients with Stargardt's Macular Dystrophy (SMD).
Respiratory movement during radiotherapy makes it difficult to hit the right treatment target and this in turn can lead to an under-dose of radiation to the tumour, or a potentially toxic over-dose to the surrounding healthy tissue. Getting this right is a real challenge for the radiotherapist, but new techniques are helping to deliver the correct dose to the right place, the 31st conference of the European Society for Radiotherapy and Oncology (ESTRO 31) will hear today.
› Verified 6 days ago
Trung Ly Tran, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 2708 S Rife Medical Ln Ste 210, Rogers, AR 72758 Phone: 479-338-3888 Fax: 479-338-4453 |